JAGX · XBRL financial data

Jaguar Health financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (JAGX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Apr 20, 2026	Q2 FY26†Jun 30, 2026
Revenue	2,813	2,300*	2,351	2,721	3,108	3,509*	2,214	2,979	3,083	3,235*	—	1,225
Cost of revenue	514	687*	430	427	541	557*	515	527	532	year only	—	1,031
Cost of goods and services sold	—	—	—	—	—	—	—	97	0*	0*	—	—
Research and development	6,081	3,463*	4,312	3,653	4,043	4,534*	3,730	3,265	3,658	14,313*	—	3,336
General and administrative	3,533	3,805*	4,381	4,314	3,776	3,860*	4,897	4,727	4,134	4,886*	—	4,450
Operating income (loss)	(8,787)	(7,557)*	(8,215)	(7,197)	(7,262)	(8,157)*	(9,421)	(8,007)	(7,238)	(21,242)*	—	(7,597)
Interest expense	500	248*	611	(108)	(162)	(110)*	(56)	(15)	6	132*	—	161
Other income (expense)	(70)	256*	234	(729)	168	378*	112	322	(94)	(297)*	—	378
Income tax expense (benefit)	0	0*	0	0	0*	0*	0	0	—	year only	—	0
Net income (loss)	(7,778)	(9,170)*	(9,226)	(9,492)	(9,854)	28,533*	(10,464)	(10,407)	(9,502)	(23,202)*	—	—
Earnings per share, basic‡ USD per share	(17,821,499.86)	—	(2,813,921.03)	(3,164,160.40)	(822,368.42)	—	(523,182.96)	(321,428.57)	(196,741.85)	—	—	(15.70)
Earnings per share, diluted‡ USD per share	(17,821,499.86)	—	(2,813,921.03)	(3,164,160.40)	(822,368.42)	—	(523,182.96)	(321,428.57)	(196,741.85)	—	—	(15.70)
Weighted average shares, basic‡ thousands of shares	0	—	0	0	0	—	0	0	0	—	—	809
Weighted average shares, diluted‡ thousands of shares	0	—	0	0	0	—	0	0	0	—	—	809

‡ Per-share figures and share counts are adjusted for the 1-for-59.880239520958085 stock split (May 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (March 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-35.714285714285715 stock split (June 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (April 2026); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-35.08771929824561 stock split (June 2026); filings made before it reported them unadjusted.
† Share count changed about 4x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 16857x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (JAGX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Apr 20, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	3,226	6,469	11,671	16,049	13,269	8,002	5,690	2,207	3,527	968	—	3,788
Accounts receivable	1,674	1,967	1,512	1,299	1,249	1,527	1,223	1,173	1,437	1,521	—	8
Inventory	8,379	9,189	9,020	9,556	9,674	10,345	10,555	10,719	10,628	8,599	—	7,316
Prepaid and other current assets	8,609	10,121	11,309	13,142	12,394	12,204	12,805	13,661	13,743	2,216	—	3,429
Total current assets	22,059	27,963	33,714	40,111	36,643	32,198	30,439	27,903	29,402	20,345	—	17,533
Property and equipment, net	511	496	484	488	476	464	452	441	483	463	—	417
Right-of-use asset	824	1,176	1,289	1,176	1,057	936	1,211	1,138	1,062	1,000	—	1,011
Total assets	45,380	50,763	55,389	61,459	58,466	53,425	51,460	48,268	49,472	38,323	—	34,194
Accounts payable	5,133	4,974	3,320	4,093	4,552	5,286	7,028	6,617	8,443	8,686	—	4,793
Accrued liabilities	3,288	3,798	3,461	3,339	3,297	1,911	2,101	3,603	4,175	4,166	—	4,712
Total current liabilities	12,456	13,987	17,814	19,133	19,874	19,704	28,208	29,218	36,122	40,654	—	25,380
Lease liability, non-current	351	886	873	812	754	686	998	960	918	892	—	873
Total liabilities	43,964	45,866	41,086	42,396	42,883	44,446	48,145	41,388	45,113	57,011	—	29,273
Accumulated deficit	(299,079)	(308,248)	(317,215)	(326,707)	(336,561)	(346,482)	(356,946)	(367,353)	(376,855)	(399,916)	—	(403,749)
Total liabilities and equity	45,380	50,763	55,389	61,459	58,466	53,425	51,460	48,268	49,472	38,323	—	34,194

† Share count changed about 4x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 16857x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (JAGX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Apr 20, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(7,778)	(9,170)*	(9,226)	(9,492)	(9,854)	28,533*	(10,464)	(10,407)	(9,502)	(23,202)*	—	—
Stock-based compensation	528*	577*	581	383*	305*	372*	301	279*	135*	116*	—	171*
Depreciation and amortization	504*	502*	501	447*	474*	478*	479	478*	479*	477*	—	473*
Net cash from operating activities	(6,790)*	(7,451)*	(7,047)	(8,170)*	(6,341)*	(7,826)*	(7,316)	(6,193)*	(4,689)*	(5,488)*	—	(5,338)*
Purchases of property and equipment	0*	—	—	—	0*	0*	—	—	—	—	—	—
Net cash from investing activities	0*	—	—	—	0*	(215)*	—	—	—	13*	—	—
Net cash from financing activities	1,409*	10,650*	12,268	12,574*	3,530*	2,830*	4,966	2,655*	6,259*	9,790*	—	1,862*
Net change in cash	(5,401)*	3,243*	5,202	4,378*	(2,780)*	(5,267)*	(2,314)	(3,481)*	1,320*	4,305*	—	(3,474)*

† Share count changed about 4x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 16857x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.